Over the past 12 months, 1 insider at FIBROGEN INC filed 2 open-market SEC Form 4 transactions on FGEN: 2 purchases worth $34K and 0 sales worth $0. Insiders have been net buyers over this period. The most recent filing was on Nov 17, 25.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Nov 17, 25 | Thane WettigCEO | BUY | 2.7K | $9.10 | $25K |
| Nov 13, 25 | Thane WettigCEO | BUY | 1.0K | $9.18 | $9K |
| Jun 30, 25 | James A SchoeneckDirector | BUY | 23.6K | $5.07 | $119K |
| Mar 24, 25 | Thane WettigCEO | BUY | 145.0K | $0.35 | $51K |
| Mar 21, 25 | James A SchoeneckDirector | BUY | 50.0K | $0.34 | $17K |
| Mar 20, 25 | James A SchoeneckDirector | BUY | 250.0K | $0.35 | $88K |
| Jun 12, 24 | Deyaa AdibChief Medical Officer | BUY | 22.1K | $1.17 | $26K |
| Mar 7, 24 | Thane WettigCEO | BUY | 50.0K | $1.91 | $96K |
| Sep 1, 23 | Jeffrey William HendersonDirector | SELL | 2.0K | $1.03 | $2K |
| Aug 4, 23 | Jeffrey William HendersonDirector | SELL | 2.0K | $1.91 | $4K |
| Jul 11, 23 | Jeffrey William HendersonDirector | SELL | 2.0K | $2.69 | $5K |
| Jul 7, 23 | Enrique A ConternoChief Executive Officer | SELL | 1.9K | $2.80 | $5K |
| Jun 23, 23 | Thane WettigChief Commercial Officer | SELL | 791 | $16.53 | $13K |
| Jun 14, 23 | Christine ChungSVP, China Operations | SELL | 5.3K | $17.46 | $87K |
| Jun 13, 23 | Christine ChungSVP, China Operations | SELL | 6.3K | $17.60 | $110K |
| Jun 9, 23 | Suzanne BlaugDirector | SELL | 5.2K | $17.51 | $91K |
| Jun 9, 23 | Aoife BrennanDirector | SELL | 2.7K | $17.52 | $48K |
| Jun 9, 23 | Benjamin CravattDirector | SELL | 2.2K | $17.51 | $38K |
| Jun 9, 23 | Jeffrey L EdwardsDirector | SELL | 4.6K | $17.51 | $81K |
| Jun 8, 23 | Jeffrey William HendersonDirector | SELL | 5.0K | $17.69 | $88K |
| Jun 8, 23 | Maykin HoDirector | SELL | 6.2K | $17.68 | $110K |
| Jun 7, 23 | Christine ChungSVP, China Operations | SELL | 1.5K | $17.04 | $26K |
| Jun 7, 23 | Enrique A ConternoChief Executive Officer | SELL | 6.1K | $17.04 | $104K |
| Jun 7, 23 | Mark EisnerEVP, Chief Medical Officer | SELL | 2.0K | $17.04 | $35K |
| Jun 7, 23 | Juan GrahamChief Financial Officer | SELL | 1.1K | $17.04 | $18K |
| Jun 7, 23 | James A SchoeneckDirector | SELL | 7.1K | $18.03 | $128K |
| Jun 7, 23 | Thane WettigChief Commercial Officer | SELL | 1.3K | $17.04 | $22K |
| Jun 2, 23 | Mark EisnerEVP, Chief Medical Officer | SELL | 1.1K | $18.83 | $21K |
| Apr 10, 23 | Enrique A ConternoChief Executive Officer | SELL | 1.9K | $19.52 | $36K |
| Apr 4, 23 | Christine ChungSVP, China Operations | SELL | 6.6K | $18.78 | $124K |
| Apr 4, 23 | Mark EisnerChief Medical Officer | SELL | 9.2K | $18.78 | $172K |
| Mar 23, 23 | Thane WettigChief Commercial Officer | SELL | 905 | $18.71 | $17K |
| Mar 10, 23 | Christine ChungSVP, China Operations | SELL | 4.7K | $20.20 | $95K |
| Mar 10, 23 | Enrique A ConternoChief Executive Officer | SELL | 19.5K | $20.20 | $394K |
| Mar 10, 23 | Mark EisnerChief Medical Officer | SELL | 6.3K | $20.20 | $126K |
| Mar 10, 23 | Juan GrahamChief Financial Officer | SELL | 2.3K | $20.20 | $47K |
| Mar 10, 23 | Thane WettigChief Commercial Officer | SELL | 4.7K | $20.20 | $96K |
| Mar 8, 23 | Christine ChungSVP, China Operations | SELL | 8.4K | $21.16 | $177K |
| Mar 8, 23 | Enrique A ConternoChief Executive Officer | SELL | 24.7K | $21.16 | $522K |
| Mar 8, 23 | Mark EisnerChief Medical Officer | SELL | 7.4K | $21.16 | $156K |
| Mar 8, 23 | Juan GrahamChief Financial Officer | SELL | 2.7K | $21.16 | $58K |
| Mar 8, 23 | Thane WettigChief Commercial Officer | SELL | 6.3K | $21.16 | $133K |
| Mar 2, 23 | Mark EisnerChief Medical Officer | SELL | 1.2K | $21.87 | $26K |
| Jan 6, 23 | Enrique A ConternoChief Executive Officer | SELL | 1.5K | $19.95 | $31K |
| Dec 23, 22 | Thane WettigChief Commercial Officer | SELL | 734 | $15.80 | $12K |
| Dec 12, 22 | Juan GrahamChief Financial Officer | SELL | 1.4K | $14.50 | $20K |
| Dec 9, 22 | Juan GrahamChief Financial Officer | SELL | 781 | $14.90 | $12K |
| Dec 8, 22 | Christine ChungSVP, China Operations | SELL | 2.6K | $15.79 | $41K |
| Dec 8, 22 | Enrique A ConternoChief Executive Officer | SELL | 2.5K | $15.79 | $40K |
| Dec 8, 22 | Juan GrahamChief Financial Officer | SELL | 5.3K | $15.47 | $78K |
Over the past 12 months, insiders at FIBROGEN INC filed 2 open-market purchases worth $34K and 0 sales worth $0 on FGEN, which makes them net buyers over the period. The most recent Form 4 was filed on Nov 17, 25.
The largest recent open-market FGEN insider purchase in our data was $119K by James A Schoeneck, Director, filed on Jun 30, 25.
1 different insider at FIBROGEN INC filed open-market SEC Form 4 transactions on FGEN over the last 12 months.
InsiderTape plots every FGEN insider buy and sell directly on the price chart and flags new SEC Form 4 filings as they arrive, with cluster detection and buy/sell pressure. The data updates daily from SEC EDGAR.
InsiderTape plots every FIBROGEN INC insider buy and sell on the price chart, with buy/sell pressure, cluster detection, and alerts the moment new Form 4s hit. Start a free 7-day trial, cancel anytime.
Does it work? In five years of data, insider clusters beat the Russell 2000 about 60% of the time and the CFO's buy was the sharpest signal of all. See the backtest →
START FREE TRIAL →